Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
This article was originally published in Pharmaceutical Approvals Monthly
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
You may also be interested in...
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.
Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.